Molnupiravir is an antiviral medication targeted for tackling COVID-19 infections. It functions by disrupting the replication process of the virus, thereby inhibiting its spread within the body. Through clinical trials , it has shown promise in reducing symptoms and the severity of illness. This is especially remarkable as it can be conveniently administered at home, potentially alleviating the strain on healthcare systems. However, as with any medication, it is imperative to consult with healthcare professionals beforehand, as they can offer guidance on its suitability and possible side effects.
Molnupiravir is an antiviral medication developed to combat infections caused by RNA viruses, such as the SARS-CoV-2 virus behind COVID-19. It falls under the family of drugs known as nucleoside analogues , which work by hindering the replication process of viruses.
| Product Name: | Molnupiravir |
|---|---|
| Generic Name: | EIDD-2801 |
| CAS Number: | 2349386-89-4 |
| COA: | Available |
| Manufacturer: | LongilatBio |
| Country of Origin: | China |
| Shelf Life: | 2 Years |
| Shipping Method: | Air (UPS, FedEx, TNT, EMS) or Sea |
Shipping:
1~25kgs packaging: Aluminium bag inside, Carton box outside.
25kgs packaging: Plastic bag inside, Fiber drum outside
